<i>KRAS</i> Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer.

Cancers (Basel) · 2022 · PMC9103674 · PMID 35565194

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Among these, the retrospective analysis of the phase 3 study KEYNOTE042 indicated a clear trend towards better OS in the KRAS MUT group when comparing first-line ICB versus platinum-containing chemotherapy (28 vs. 11 months) than for the patients with KRAS WT (15 vs. 12 months) [ 45 ], albeit only 301 out of 782 patients were molecularly assessed for KRAS status, among which 69 KRAS MUT cases were identified.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.